TABLE 2.

Protection obtained by immunization with dimeric OspC at clinically relevant dosages

Group	No. of cultures positive/total no.						No. of mice positive/total no.	% mice protected
	Skin	Ear	Joint	Bladder	Heart	All sites
Alum only	6/6	6/6	6/6	6/6	6/6	30/30	6/6	0
0.1 μg D-OspCB31 + alum	1/6	1/6	0/6	1/6	1/6	4/30	1/6	83
1.0 μg D-OspCB31 + alum	0/6	0/6	0/6	0/6	0/6	0/30	0/6	100
10 μg D-OspCB31 + alum	1/6	0/6	1/6	1/6	1/6	4/30	1/6	83
0.1 μg M-OspCB31 + alum	3/3	3/3	3/3	3/3	3/3	15/15	3/3	0
1.0 μg M-OspCB31 + alum	3/3	3/3	3/3	3/3	3/3	15/15	3/3	0
10 μg M-OspCB31 + alum	2/3	2/3	2/3	2/3	2/3	10/15	2/3	33
100 μg M-OspCB31 + alum	4/6	4/6	4/6	4/6	4/6	20/30	4/6	33